Joseph A Thie1. 1. University of Tennessee, 12334 Bluff Shore Dr., Knoxville, TN 37922, USA. jathie@utk.edu
Abstract
PURPOSE: The intention here is to enhance the usefulness of the Gjedde-Patlak plot of dynamic positron emission tomography (PET) tracer uptake. Two additional parameters closely related to the physiologically significant and diagnostically useful phosphorylation rate k (3) are therefore studied. Additionally, their inter-institutional transportability is examined. METHODS: The two traditional parameters obtained from a Patlak plot are its slope Ki and its usually ignored tissue/plasma (=Q/Cp) axis intercept V. As a useful result, a normalized uptake rate may be defined as k=Ki /V. This is can be theoretically close to k (3). Similar to this an alternative normalized uptake rate is defined as k (3)' =Ki /V '. Here, V ' would be a composite of model rate constants, reasonably known a priori, and the measured V so as to depend less on errors in the latter. Parameter determination demonstrations utilize data from the 2-deoxy-2-[F-18]fluoro-D-glucose(FDG)-PET literature. RESULTS: Using median k (i) values from 24 FDG dynamic studies and algebraic relationships, on average: k=1.07 k (3)(r=0.97), and k (3)' =0.95k (3) (r=0.91). A skeletal muscle case also demonstrates agreements with k (3). For liver malignancies k and k (3)' can be diagnostically slightly superior to Ki. Unaffected by institutionally dependent Q and Cp calibrations and methods, these can be more robust than Ki in a number of circumstances. CONCLUSION: Two studied physiologically meaningful parameters, close to the diagnostically important k (3), can supplement Ki and enhance Patlak analysis by appropriately utilizing normally ignored information. Hitherto, k (3) was obtainable only by complex nonlinear least squares compartmental model analysis. The additional parameters can have more robust inter-institutional transportability than Ki.
PURPOSE: The intention here is to enhance the usefulness of the Gjedde-Patlak plot of dynamic positron emission tomography (PET) tracer uptake. Two additional parameters closely related to the physiologically significant and diagnostically useful phosphorylation rate k (3) are therefore studied. Additionally, their inter-institutional transportability is examined. METHODS: The two traditional parameters obtained from a Patlak plot are its slope Ki and its usually ignored tissue/plasma (=Q/Cp) axis intercept V. As a useful result, a normalized uptake rate may be defined as k=Ki /V. This is can be theoretically close to k (3). Similar to this an alternative normalized uptake rate is defined as k (3)' =Ki /V '. Here, V ' would be a composite of model rate constants, reasonably known a priori, and the measured V so as to depend less on errors in the latter. Parameter determination demonstrations utilize data from the 2-deoxy-2-[F-18]fluoro-D-glucose(FDG)-PET literature. RESULTS: Using median k (i) values from 24 FDG dynamic studies and algebraic relationships, on average: k=1.07 k (3)(r=0.97), and k (3)' =0.95k (3) (r=0.91). A skeletal muscle case also demonstrates agreements with k (3). For liver malignancies k and k (3)' can be diagnostically slightly superior to Ki. Unaffected by institutionally dependent Q and Cp calibrations and methods, these can be more robust than Ki in a number of circumstances. CONCLUSION: Two studied physiologically meaningful parameters, close to the diagnostically important k (3), can supplement Ki and enhance Patlak analysis by appropriately utilizing normally ignored information. Hitherto, k (3) was obtainable only by complex nonlinear least squares compartmental model analysis. The additional parameters can have more robust inter-institutional transportability than Ki.
Authors: Jeffrey Tseng; Lisa K Dunnwald; Erin K Schubert; Jeanne M Link; Satoshi Minoshima; Mark Muzi; David A Mankoff Journal: J Nucl Med Date: 2004-11 Impact factor: 10.057
Authors: Alexander M Spence; Mark Muzi; David A Mankoff; S Finbarr O'Sullivan; Jeanne M Link; Thomas K Lewellen; Barbara Lewellen; Pam Pham; Satoshi Minoshima; Kristin Swanson; Kenneth A Krohn Journal: J Nucl Med Date: 2004-10 Impact factor: 10.057
Authors: T Torizuka; N Tamaki; T Inokuma; Y Magata; S Sasayama; Y Yonekura; A Tanaka; Y Yamaoka; K Yamamoto; J Konishi Journal: J Nucl Med Date: 1995-10 Impact factor: 10.057
Authors: W J Jagust; J P Seab; R H Huesman; P E Valk; C A Mathis; B R Reed; P G Coxson; T F Budinger Journal: J Cereb Blood Flow Metab Date: 1991-03 Impact factor: 6.200